(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 November 2013 (14.11.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/169520 A1

(51) International Patent Classification:
A61K 9/48 (2006.01) *A61P 31/14* (2006.01)
A61K 31/4709 (2006.01)

(21) International Application Number:
PCT/US2013/038770

(22) International Filing Date:
30 April 2013 (30.04.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/643,454 7 May 2012 (07.05.2012) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Route 206 and ProvinceLine Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventor: **PERRONE, Robert Kevin**; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, New Jersey 08903 (US).

(74) Agents: **MINGO, Pamela, A.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: SOLUBILIZED CAPSULE FORMULATION OF 1,1-DIMETHYLETHYL [(1S)-1-{[(2S,4R)-4-(7-CHLORO-4METHOXY-ISOQUINOLIN-1-YLOXY)-2-({(1R,2S)-1-[(CYCLOPROPYLSULFONYL)CARBAMOYL]-2-ETHENYLCYCLOPROPYL}CARBAMOYL)PYRROLIDIN-1-YL]CARBONYL}-2,2-DIMETHYLPROPYL]CARBAMATE

(57) **Abstract**: The present disclosure includes various embodiments directed to a solubilized capsule formulation of asunaprevir, 1,1-dimethylethyl [(1S)-1-{[(2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrr olidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate, and to methods including asunaprevir.




FIG. 1

WO 2013/169520 A1